Apyx Medical Corporation (APYX) announced that the U.S. FDA has granted expanded 510(k) clearance for its AYON Body Contouring System to include power liposuction capability.
The clearance adds a second advanced liposuction modality to the platform, designed to enhance fat removal efficiency and reduce surgeon effort and operating room time.
AYON is a surgeon-designed body contouring system that integrates fat removal, closed loop contouring, and Renuvion's tissue contraction technology into a single platform. With the addition of power liposuction, surgeons can now perform multiple body contouring modalities within one system, streamlining workflow and supporting improved patient outcomes.
Apyx Medical plans a limited commercial launch of the new function, working closely with early adopters to refine training and utilization before scaling broader adoption. CEO Charlie Goodwin described AYON as a "gold-standard system in surgical aesthetics," highlighting its potential to drive greater market demand.
The company, known for its Renuvion and J-Plasma technologies, continues to expand its surgical aesthetics portfolio. AYON's expanded clearance represents a milestone in Apyx's strategy to deliver comprehensive, evidence-based solutions for body contouring and aesthetic surgery.
APYX has traded between $1.08 and $4.50 over the past year. The stock closed Friday's trading (May 8, 2026) at $3.67, up 3.09%. In pre-market trading, the stock is at $3.86, up 5.18%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.